Companies Collaborate to Set a New Standard for Patient-Centric Digital Clinical Trials

BRUSSELS and PLEASANTON, California, May 23, 2023 /PRNewswire/ — Veeva Systems (NYSE: VEEV) and UCB, a global biopharmaceutical company, today announced a collaboration that will focus on technology solutions aimed at improving the patient experience and the efficiency of the trials. The collaboration will see UCB adopt Veeva ePRO and Veeva eConsent, to provide a patient-centric digital experience to study participants and actively influence the strategic direction of these and other applications based on learnings. Together, Veeva and UCB aim to set a new industry standard for digital clinical trials with multiple applications that meet the unique needs of patients.

“The partnership between UCB and Veeva presents a significant opportunity to drive progress in conducting clinical trials,” said Iris Loew-Friedrich, UCB executive vice president and chief medical officer. By offering digital clinical trials, we reduce the burden on participants and sites, improve trial accessibility, and ensure that patients are at the center of everything we do.”

Veeva ePRO simplifies the design, management, and completion of electronic patient-reported results (ePRO) with seamless data flow between sponsors, facilities, and patients. Veeva eConsent makes it simple to set up, fill out, and review consent for patients, sites, and study teams. Both apps are available to patients through MyVeeva for Patients, which provides one access point for all your clinical trial actions, scheduling, and communications. Veeva ePRO and Veeva eConsent are part of the Veeva Vault Clinical Suite, a set of integrated capabilities that simplify the clinical trial technology landscape for both clinical operations and clinical data management.

“We are excited to partner with UCB to advance patient-centric digital trials,” said Veeva CEO Peter Gassner. “His input from him will help advance Veeva’s focus toward solutions that make digital trials work even better for sponsors, sites, and patients.”

Edwin Erckens, UCB’s chief digital technology officer, added: “UCB’s collaboration with Veeva is further evidence of our continued effort to drive digital business transformation. By leveraging our collective expertise, we can push the boundaries of what technology can can do to improve the clinical trial process.

About UCBUCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people with severe immune system or central nervous system diseases. With approximately 8,700 people in some 40 countries, the company generated revenues of €5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB.

About Veeva Systems Veeva is the world leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, from the world’s largest biopharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit

Veeva’s Forward-Looking Statements This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we are under no obligation to update such statements. There are numerous risks that could adversely affect our results, including the risks and uncertainties disclosed in our Form 10-K filing for the fiscal year ended January 31, 2023, which you can find here (pages 9 and 10 contain a summary of risks that may affect our business), and in our subsequent filings with the SEC, which can be accessed at

Photo –… Logo –…

View original content: